A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer.

被引：0
|
作者：
Shen, Jie
Kong, Weiwei
Zhu, Sihui
Liu, Baorui
机构：
[1] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Nanjing, Peoples R China
[2] Nanjing Univ, Comprehens Canc Ctr, Drum Tower Hosp, Med Sch, Nanjing, Peoples R China
[3] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[4] Nanjing Univ, Comprehens Canc Ctr, Med Sch, Clin Canc Inst,Drum Tower Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis
    Zheng, Kanglian
    Fu, Shijie
    Zhu, Xu
    Cao, Guang
    Xu, Liang
    Liu, Peng
    Gao, Song
    Xu, Haifeng
    Guo, Jianhai
    Chen, Hui
    Liu, Wei
    Xu, Da
    Wang, Lijun
    Yan, Xiaoluan
    Bao, Quan
    Wu, Jianhui
    Wang, Kun
    Zhou, Jun
    Hao, Chunyi
    Xing, Baocai
    Shen, Lin
    Yang, Renjie
    Wang, Xiaodong
    HEPATOBILIARY SURGERY AND NUTRITION, 2025,
  • [22] Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Li, Jibin
    Cheng, Xiaqin
    Zhang, Rong
    Huang, Xin
    Huang, Yongwen
    Li, Qiaqia
    Qiu, Ya
    Zheng, Min
    Zhu, Xiaofeng
    Li, Jundong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (05)
  • [23] Meta-analysis of the efficacy and safety of anlotinib combined with chemotherapy in the treatment of small cell lung cancer.
    Gao, Ting
    Zhao, Peiwen
    Li, Juanzhi
    Li, Yingjie
    Li, Xinxin
    He, Xiaopeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study
    Zhang, Cheng-Sheng
    Zeng, Zhi-Ming
    Zhuo, Man-Yun
    Luo, Jing-Ru
    Zhuang, Xiao-Hong
    Xu, Jun-Nv
    Zeng, Jie
    Ma, Jie
    Lin, Hai-Feng
    ONCOLOGIST, 2023, : e1239 - e1247
  • [25] A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
    Xu, Mingfang
    Pu, Yu
    Jiang, Yuzhu
    Liu, Hong
    Feng, Yan
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    Li, Mengxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 395 - 395
  • [26] Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer
    Yu, Wei
    Tao, Qiaomeng
    Zhang, Yufeng
    Yi, Fengming
    Feng, Long
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [27] A retrospective study to evaluate the safety and efficacy of anlotinib plus camrelizumab in management of advanced retroperitoneal sarcoma.
    Wu, Jianhui
    Qiu, Hui
    Lv, Ang
    Liu, Bonan
    Liu, Qiao
    Li, Chengpeng
    Liu, Daoning
    Wang, Zhen
    Tian, Xiuyun
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: A preliminary analysis of safety and efficacy of an open-label phase II clinical study
    Liu, T.
    Li, W.
    Yu, Y.
    Guo, X.
    Xu, X.
    Wang, Y.
    Li, Q.
    Wang, Y.
    Cui, Y.
    Liu, H.
    Zhang, S.
    Wang, F.
    Yao, M.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S261 - S261
  • [29] ASO Visual Abstract: The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study
    Chen, Jia-ying
    Huang, Nai-si
    Wei, Wen-jun
    Hu, Jia-qian
    Cao, Yi-ming
    Shen, Qiang
    Lu, Zhong-wu
    Wang, Yu-long
    Wang, Yu
    Ji, Qing-hai
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (04) : 2366 - 2367
  • [30] The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer (NeoSACT)
    Zhang, Liulu
    Yang, Mei
    Yang, Ciqiu
    Zhu, Teng
    Gao, Hong-Fei
    Wang, Kun
    CANCER RESEARCH, 2024, 84 (09)
12345